JP2022529824A5 - - Google Patents

Info

Publication number
JP2022529824A5
JP2022529824A5 JP2021562908A JP2021562908A JP2022529824A5 JP 2022529824 A5 JP2022529824 A5 JP 2022529824A5 JP 2021562908 A JP2021562908 A JP 2021562908A JP 2021562908 A JP2021562908 A JP 2021562908A JP 2022529824 A5 JP2022529824 A5 JP 2022529824A5
Authority
JP
Japan
Application number
JP2021562908A
Other languages
Japanese (ja)
Other versions
JP2022529824A (ja
JP7770924B2 (ja
JPWO2020219668A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029513 external-priority patent/WO2020219668A1/en
Publication of JP2022529824A publication Critical patent/JP2022529824A/ja
Publication of JP2022529824A5 publication Critical patent/JP2022529824A5/ja
Publication of JPWO2020219668A5 publication Critical patent/JPWO2020219668A5/ja
Priority to JP2025081069A priority Critical patent/JP2025127483A/ja
Application granted granted Critical
Publication of JP7770924B2 publication Critical patent/JP7770924B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562908A 2019-04-24 2020-04-23 Ｒａｓ変異体癌を治療するための組成物および方法 Active JP7770924B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025081069A JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838065P 2019-04-24 2019-04-24
US62/838,065 2019-04-24
PCT/US2020/029513 WO2020219668A1 (en) 2019-04-24 2020-04-23 Compositions and methods for treating ras-mutant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025081069A Division JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Publications (4)

Publication Number Publication Date
JP2022529824A JP2022529824A (ja) 2022-06-24
JP2022529824A5 true JP2022529824A5 (https=) 2023-05-01
JPWO2020219668A5 JPWO2020219668A5 (https=) 2023-05-01
JP7770924B2 JP7770924B2 (ja) 2025-11-17

Family

ID=72941253

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562908A Active JP7770924B2 (ja) 2019-04-24 2020-04-23 Ｒａｓ変異体癌を治療するための組成物および方法
JP2025081069A Pending JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025081069A Pending JP2025127483A (ja) 2019-04-24 2025-05-14 Ｒａｓ変異体癌を治療するための組成物および方法

Country Status (5)

Country Link
US (1) US20220193109A1 (https=)
EP (1) EP3959199A4 (https=)
JP (2) JP7770924B2 (https=)
CN (1) CN114025772A (https=)
WO (1) WO2020219668A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149941B1 (en) 2020-05-15 2025-09-03 Algen Biotechnologies, Inc. Certain chemical compositions and methods of use thereof
CN113952359A (zh) * 2021-11-19 2022-01-21 大连理工大学盘锦产业技术研究院 顺铂与Tri-1的联合抗肺癌药物组合物及其应用
EP4551214A1 (fr) * 2022-07-05 2025-05-14 Association Française contre les Myopathies Utilisation de l'ebselen ou l'un de ses derives pour traiter des pathologies ou dysfonctionnements des mitochondries

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CA2718400A1 (en) * 2008-03-11 2009-09-17 The General Hospital Corporation Piperlongumine and piperlongumine analogs for use in the treatment of cancer
EP2954328A1 (en) * 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
CN105263523A (zh) * 2013-03-15 2016-01-20 米尔纳疗法公司 使用微rna和egfr-tki抑制剂的联合癌症治疗
CA2958683A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by prostratin
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
GB201514021D0 (en) * 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
WO2018145090A1 (en) * 2017-02-06 2018-08-09 New York University Methods of treating cancers having a deregulated nrf2/keap1 pathway
EA201992781A1 (ru) * 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
WO2018218087A1 (en) * 2017-05-24 2018-11-29 K-Gen, Inc. Methods of cancer treatment
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法

Similar Documents

Publication Publication Date Title
CL2025004153A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso.
JP2022529824A5 (https=)
CN306192597S (https=)
CN305987510S (https=)
CN305560072S (https=)
CN305559043S (https=)
CN305528974S (https=)
CN305581216S (https=)
CN305554442S (https=)
CN305544553S (https=)
CN305543627S (https=)
CN305541336S (https=)
CN305540498S (https=)
CN305539768S (https=)
CN305581324S (https=)
CN305536128S (https=)
CN305535910S (https=)
CN305534722S (https=)
CN305533480S (https=)
CN305533208S (https=)
CN305532082S (https=)
CN305530732S (https=)
CN305557857S (https=)
CN306195612S (https=)
CN306194673S (https=)